Back to dashboard
CommercialAdministrativeLow impact

08.01.85b, Tebentafusp-tebn (Kimmtrak®)

Independence Blue Cross·PA · Oncology, Pharmacy·Pharmacy
Effective date
Not stated
We identified it
Jun 19, 2026
Days to comply
—

Summary

Independence Blue Cross reissued Policy 08.01.85b for Tebentafusp-tebn (Kimmtrak®) on 11/26/2025 with no substantive changes to coverage criteria. The policy continues to cover this drug as first-line treatment for HLA-A*02:01–positive unresectable or metastatic uveal melanoma in treatment-naïve patients. HCPCS code J9274 remains the active billing code for this medication.

Action Required

Action needed
No immediate action required. This is an administrative reissuance with no changes to coverage, coding, or billing requirements. Billing team should note the 11/26/2025 reissue date for audit trail purposes. Continue billing tebentafusp-tebn claims using HCPCS code J9274 with existing prior authorization requirements (HLA-A*02:01 genotype confirmation and documentation of no prior systemic therapy for metastatic/advanced uveal melanoma or liver-directed therapy).

Affected Billing Codes

J9274

Related policy hubs